skip to Main Content

Masktag: Accessory Device For Face Coverings

Accessory Device for Face Coverings

MaskThe described invention pertains to an accessory device designed to address various issues associated with the use of face coverings, surgical masks, and filtering facepieces, especially in the context of the COVID-19 pandemic. Here’s an overview of the problem it aims to solve and the features it offers:

Problem Statement:

The widespread use of face coverings and masks in response to health emergencies, such as the COVID-19 pandemic, has highlighted several challenges and shortcomings associated with these protective devices. Some of the key issues include:

1. Difficulty in recognizing one’s mask after temporary removal, which poses a risk of using a contaminated mask.
2. Impaired recognizability of the wearer due to the partial coverage of the face by the mask, particularly exacerbated when wearing additional accessories like glasses or hats.
3. Accumulation of unpleasant odors inside the face covering, primarily caused by the user’s breath.
4. Build-up of microbial and viral load within the face covering due to prolonged use and favorable microclimatic conditions, potentially leading to health risks.

Summary of the Invention:

The invention aims to address these challenges by providing an accessory device with dual functionality:

1. Diffuser Functionality: The device serves as a diffuser for fragrances, scents, and essential oils. This feature helps mask unpleasant odors inside the face covering and may also include antibacterial and antiviral ingredients to reduce microbial and viral load.

2. Identification Signal: The device functions as a recognition signal for the face covering or mask, enabling users to easily identify their own mask even after temporary removal. This helps prevent the accidental use of contaminated masks.

Key Features:

Reusability: The device is designed to be reusable, allowing it to be transferred to a new face covering or mask once the previous one is exhausted.

Comfort and Effectiveness: The device is intended to be comfortable to wear and effective in eliminating unpleasant odors, without causing discomfort during use.

Kit Option: The invention may also be offered as a kit, including at least one face covering or mask and at least one accessory device with diffuser and identification functionality.

Patent Application Number WO: 2022/018583
Patent Application Number India: 202317006763

For more details about technology: Click Here

Patent Protected Modular Urinal for Bed Ridden People

About Us

Modular UrinalIIPRD is representing Peeshcute in an IP Licensing mandate for a technology which Empowers Convenience and Independence for those with limited mobility issues.

Peeschute’s modular urinal tech has been carefully designed considering factors like non-invasiveness, ease of use, hygiene, sustainability, reduced dependability and reduced risk of infections.

  • Established in 2018, Peeschute is a renowned brand specializing in developing innovative solutions for sanitation.
  • Peeschute has developed urinal products for travel, healthcare/homecare and outdoor spaces.
  • Peeschute’s flagship product includes pocket sized disposable urine bags which solidifies up to 850 ml of urine instantly to keep it leak proof, odorless and hygienic.
  • Peeschute’s products has been accolated with national and international attention including media, organizational collaborations with government and non-government bodies.

Patent Application No: 202221026004
Registrations Design Number: 373040-001 and 373041-001

For more details about technology: Click Here

“Resoil” presented by Envit Ltd.

ReSoil® is internationally patented, groundbreaking remediation solution that enables closed-loop removal of heavy metals from contaminated soils through a zero-emission process with no wastewater, while preserving soil as a natural substrate.


• Soil contamination with heavy metals is a global problem.
• Heavy metals include toxic metals such as lead (Pb), cadmium (Cd), copper (Cu) and zinc (Zn) as well as toxic metalloids such as arsenic (As) and antimony (Sb).
• Soils absorb decades of pollution from industry, intensive agriculture, traffic, waste, etc. Heavy metals are not degradable and remain in the soil.
• According to a recent conservative estimate, there are 2.8 million potentially contaminated sites in the EU (EEA, 2023).
• In China, 1/6 of the total cultivated area is contaminated with heavy metals (Yao et al., Proc Env Sci 2012, 16, 722-729).
• In New York, 71% of garden soils exceed the limits for lead and arsenic (Chenget al., Soil Sci 2015, 180, 167-174).
• Arsenic and lead are the 1st and 2nd most dangerous environmental pollutants
(ATSDR 2017).Lead distribution in surface soil of the conterminous United States (USGS 2014).
• Arsenic is highly toxic, long-term exposure can cause cancer.
• Lead is a neurotoxin; in the USA, the average lead-related loss of cognitive ability was 2.6 IQ points per person as of
2015 (McFarland et al. PNAS 2022, 119, e2118631119

For more details about technology: Click Here

Patent Application Number: WO2022184903

Machine to Dispose off used Sanitary napkins chemically

Current methods of disposal and associated danger

1. Flushing and burying

• leads to blockages, plumbing problems
• outer layer of sanitary napkin is non-degradable
• collection of napkins in heaps block the pipeline
• pollute streams and rivers
• causes hormonal changes in wildlife – enable harmful organisms in the food chain

2. Incineration

• Harmful gas emissions: dioxin, furan, nitrogen oxides, sulphur dioxide, hydrochloric acid, mercury
• Ash produced contain heavy metals like lead, cadmium, copper, zinc
• Dioxins: cancer, immune system damage, reproductive and developmental problems.
• Halogenated hydrocarbons, acid gases – impair lung function.

Objectives of the new machine

• Disposal of sanitary napkins properly, thereby wiping out the risks involved in flushing, burying, and incineration.
• Reduce pollution and health hazards of conventional methods of sanitary waste disposal.
• Reduce cost for proper disposal of sanitary napkins, tampons, baby diapers and under pads.
• Simplify the process of sanitary waste disposal.
• Help in solving greatest problem people face daily.

Machine to dispose of Uses Sanitary NapkinKey Points of the machine

• One machine- can be used for sanitary napkins, tampons, baby diapers and under pads. (If a method to choose the option while
using the machine is implemented)
• Can be manufactured both – domestic (for households) and industrial size (waste disposal plants/ panchayats)

Patent Application Number: 298227

For more details about technology: Click Here


The Opportunity

Diabetes are Mediial DeviceBlackhawk Technologies, LLC is exclusively representing HyperMed Imaging Inc. (the“Company”) to monetize its’ assets related to a Medical Device for Tissue Oximetry for Diabetes Care. The offering includes an FDA cleared product used by clinicians and backed by 24 patent families comprising of 62 total assets.

The Company’s pioneering technology has been in service since 2006 and has been validated in third-party published papers that assessed oxyhemoglobin, deoxyhemoglobin, and oxyhemoglobin saturation in superficial tissue for diabetic patients. The Company’s FDA 510(k) cleared product, Hyper View™, quickly determines levels of oxyhemoglobin, deoxyhemoglobin and oxygen saturation in superficial tissue in a small and portable configuration.

The Company seeks a strategic acquirer/licensee with both resources and channels to fully commercialize Company’s IP assets.

The Unmet Medical Need

Most medical exams need quick and accurate determination of superficial tissue oxygenation. For example, complications in diabetes and/or peripheral arterial disease increases risk of lower limb ischemia, chronic wounds, amputation or even death.

• Over 420 million people worldwide (1 in 11 people) have diabetes and the number is increasing rapidly.
• More than 29 million Americans have diabetes. Another 86 million have prediabetes, which is 1 in 3 US adults.
• 8.5 million Americans have peripheral arterial disease and among them nearly 2 million people in the USA are living with limb loss.
• The main causes are vascular disease (54%), including diabetes and peripheral arterial disease.
• Approximately 185,000 amputations occur in the United States each year, costing over $8 billion.
• People with diabetes are at greater risk for severe peripheral arterial disease and are five times more likely to require an amputation.
• It is estimated that a low

Hyperspectral Imaging Benefits

• Non-contact color-coded images depicting concentrations of oxyhemoglobin & deoxyhemoglobin, and oxygen saturation without injectable contrast agents.
• Readings are predictive of wound healing and can be used in screening for peripheral vascular disease.
• Software tools allow clinicians to analyze specified areas within the image to localize ischemic tissue.
• Offers improved patient care with speed, ease of use, and clinical efficiency without injectable contrast or physical contact of the device with the patient.
• Safe, using visible light and spectrometer imaging to quantify light absorption in hemoglobin molecules for rapid analysis without leaving the exam room.

For more details about technology: Click Here


origion corporate Has developed a proprietary device (“IonojetTM”) that generates nitric oxide (“NO”) from atmospheric air in the form of a high-energy plasma/NO stream and delivers it to targeted locations of the body.

The plasma/NO stream has been shown in investigations to date:

(i)to be non-toxic

(ii) to generate NO activity up to 3 cm below the skin

(iii) to stimulate sustained biological activity in tissue for up to an hour after delivery of the therapy, and

(iv) to penetrate and disrupt biofilm

Has identified over 40 target indications in seven clinical areas based on NO’s recognized ability to:

  • Increase blood flow
  • Destroy pathogens (bacterial, viral and fungal)
  • Regenerate tissue
  • Control pain and inflammation

Has completed a dose-ranging feasibility clinical trial in the U.S. for initial target indication (Diabetic Foot Ulcers, “DFU”) to identify optimal dose & demonstrate preliminary safety/efficacy data for the device.

  • Has completed PoC studies in certain target indications
  • Intends to initiate PoC studies in a number of additional indications

For more details about technology: Click Here

Back To Top